With the exception of a few monogenic forms, Alzheimer disease (AD) has a complex
aetiology that is likely to involve multiple susceptibility genes and environmental factors. The …

There are currently no validated biomarkers which can be used to accurately diagnose
Alzheimer's disease (AD) or to distinguish it from other dementia-causing neuropathologies …

Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by the
progressive accumulation of amyloid-beta and neurofibrillary tangles of tau in the neocortex …

Human DNA methylation data have been used to develop biomarkers of ageing, referred to
as 'epigenetic clocks', which have been widely used to identify differences between …

DNA methylation differences in Alzheimer's disease (AD) have been reported. Here, we
conducted a meta-analysis of more than 1000 prefrontal cortex brain samples to prioritize …

In the past decade, assays that profile different aspects of the epigenome have grown
exponentially in number and variation. However, standard guidelines for researchers to …

Abstract Background Late-onset Alzheimer's disease (AD) is a complex multifactorial
affliction, the pathogenesis of which is thought to involve gene-environment interactions that …

Epigenome-wide association studies of Alzheimer's disease have highlighted
neuropathology-associated DNA methylation differences, although existing studies have …

Alzheimer's disease (AD) is characterized by specific alterations of brain DNA methylation
(DNAm) patterns. Age and sex, two major risk factors for AD, are also known to largely affect …

Background Growing evidence shows that epigenetic modifications play a role in
Alzheimer's disease (AD). We performed an epigenome-wide association study (EWAS) to …